WuXi STA was announced as the winner of Roche’s “2020 CDMO Award” for the best project-related performance of a CDMO in a given year.
The award ceremony was postponed to 2021 due to the pandemic and now was held both online and offline, Roche and WuXi STA leadership teams attended this ceremony with the project team members.
Dr. Thomas Osswald, head of external technical oversight at Roche, briefly reviewed the collaboration history with WuXi STA, especially the joint efforts for the IPP project, and praised WuXi STA as Roche’s reliable, trustworthy partner. Dr. Xiaoyong Fu, CTO and head of API business at WuXi STA, and Dr. Youchu Wang, head of early stage API business at WuXi STA, recalled the milestone moments, with thanks to Roche for its trust over the past decades and expected a stronger future collaboration to bring more therapies faster to global patients.
The WuXi STA project team was recognized for the outstanding contributions to Roche’s IPP[1] project, the HBV program, which started in 2014. WuXi STA became the first CMO in China for Roche to manufacture API for clinical supply in 2015. Since then, all teams, including process development, biocatalysis, and manufacturing etc., had made significant contributions to Roche’s different projects. WuXi STA went above and beyond Roche’s expectations by focusing on Roche’s needs to overcome challenges and achieving technical breakthroughs in tight timelines.
WuXi STA’s project teams and individual scientists received award from Roche, represented by Dr. Patrick Zheng, APAC regional category manager at Roche.
WuXi STA, a leader in the CDMO industry for twenty years, has supported 33 new drugs approved globally and products manufactured by WuXi STA have been launched in 105 countries around the world. In 2020 alone, WuXi STA served more than 470 customers worldwide. Moving forward, WuXi STA will continue to leverage its end-to-end CMC platform and industry leading technologies, along with the global standard quality systems to empower more partners to accelerate their medicines to market for the benefit of global patients.
[1] Internal code in Roche
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.
For more information, please visit: https://sta.wuxiapptec.com/
